France's Cellectis in-licenses technology from iPS Academia Japan; posts first half results

19 October 2010

French genome engineering specialist Cellectis (Alternext: ALCLS) and iPS Academia Japan have signed two separate non-exclusive agreements granting the Paris-based company worldwide access to the induced Pluripotent Stem (iPS) cells patent portfolio arising from the work of Shinya Yamanaka of the Center for iPS Cell Research and Application (CiRA) at the University of Kyoto, Japan. Financial terms of the deals were not disclosed.

The agreements allow Cellectis, a spin-out from Sanofi Pasteur, and its affiliates to research, develop and commercialize both research tools (covered by one deal) and human therapeutics or prophylactics (covered by the second accord) derived from iPS cells, in a certain range of differentiated cell lineages. Cellectis is the first company worldwide to be licensed by iPS Academia Japan under this iPS cell patent portfolio for human therapeutics and prophylactics. In the research tool field, this is the first agreement with a French company following agreements with US and German companies.

First deal for regenerative medicine

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK